Chimeric antigen receptor (CAR) T-cell therapy can lead to durable responses in patients
with relapsed/refractory hematologic malignancies. Immune effector cell–associated
neurotoxicity syndrome (ICANS) and cytokine release syndrome (CRS) are common and
may place patients at risk for longer-term cognitive impairment. This study examined
changes in cognition in the first year after CD19-directed CAR T-cell therapy for lymphoma,
as well as CAR T-cell therapy-specific risk-factors (eg, ICANS, CRS) and nonspecific risk …

Introduction: Chimeric antigen receptor (CAR) T-cell therapy can lead to durable responses
in patients with relapsed/refractory hematologic malignancies. Immune effector cell-
associated neurotoxicity syndrome (ICANS) occurs in up to 64% of patients. There is
concern that ICANS places patients at risk for longer-term cognitive impairment. This study
examined changes in patients' perceived cognition from prior to CAR T-cell therapy to days
90 and 360 in patients diagnosed with non-Hodgkins lymphoma, as well as CAR T-cell …